What Happens if Your Cholesterol or LDL is Too Low?
Very low LDL cholesterol (<30 mg/dL) is generally safe and not associated with significant adverse effects, though there may be a small increased risk of hemorrhagic stroke that requires blood pressure monitoring. 1
Cardiovascular Benefits Outweigh Risks
The evidence overwhelmingly demonstrates that achieving very low LDL-C levels provides continued cardiovascular benefit without serious safety concerns. Studies show a consistent 21% reduction in major cardiovascular events per 1 mmol/L (38.7 mg/dL) reduction in LDL-C, even when starting from levels as low as 63 mg/dL and achieving levels as low as 21 mg/dL 2. This benefit extends down to LDL-C levels below 20 mg/dL without offsetting adverse effects 3.
Specific Concerns and What the Evidence Shows
Hemorrhagic Stroke - The Main Concern
This is the only potential risk that requires clinical attention. The evidence is mixed but suggests possible increased risk:
- Some observational studies show increased hemorrhagic stroke risk at very low LDL-C levels, with one Japanese cohort showing adjusted hazard ratios of 1.65 for LDL-C 50-69 mg/dL and 2.69 for LDL-C <50 mg/dL 1
- Women with LDL-C <70 mg/dL had 2.17 times the risk of hemorrhagic stroke compared to those with LDL-C 100-130 mg/dL 1
- However, the ODYSSEY OUTCOMES trial found no increased hemorrhagic stroke risk even in patients achieving LDL-C <25 mg/dL 1
Clinical Action: Maintain tight blood pressure control in patients with very low LDL-C, particularly those with prior stroke history 4.
Cognitive Function - No Evidence of Harm
Brain cholesterol is primarily synthesized locally, not derived from circulating LDL-C 1. The most recent long-term data (2025) from extended follow-up of FOURIER/EBBINGHAUS patients showed:
- Median follow-up of 5.1 years (maximum 7.2 years) with median LDL-C of 35 mg/dL
- No cognitive impairment with executive function scores remaining stable 5
- No difference between groups achieving LDL-C <25 mg/dL versus higher levels 1
Diabetes Risk - Statin-Specific, Not LDL-Related
New-onset diabetes is associated with statin dose, not with achieving low LDL-C levels 1. Importantly, newer non-statin lipid-lowering drugs (PCSK9 inhibitors, ezetimibe) do not show this increased diabetes risk 4.
Cancer - No Association
Multiple analyses show no increased cancer risk with very low LDL-C levels achieved through lipid-lowering therapy 2, 3.
Other Safety Outcomes
No increased risk of:
- Serious adverse events
- Myalgias or myositis
- Liver enzyme elevation
- Cataracts (conflicting data, but no consistent signal) 2
Genetic Evidence Supports Safety
People with lifelong genetic conditions causing very low LDL-C (PCSK9 loss-of-function mutations, familial hypobetalipoproteinemia) live normal lives without adverse effects, providing strong evidence that very low LDL-C is physiologically tolerable 1.
Current Guideline Targets
The 2019 ESC/EAS guidelines recommend:
- LDL-C <55 mg/dL for very high-risk patients (Class I)
- LDL-C <40 mg/dL for patients with recurrent vascular events within 2 years (Class IIb) 1
The principle is "lower for longer is better" for reducing ASCVD risk 6.
Common Pitfall to Avoid
Do not de-escalate lipid-lowering therapy due to fear of very low LDL-C levels. This paradoxically exposes patients to higher cardiovascular risk without meaningful safety benefit 4. The cardiovascular mortality reduction from lower LDL-C far exceeds any small potential increase in hemorrhagic stroke risk 1.